Navigation Links
NEXUS Biosystems Acquires Tecan Group's REMP Sample Management Business

POWAY, Calif., July 15 /PRNewswire/ -- NEXUS Biosystems, Inc., a leading innovator and worldwide provider of automated sample management systems, today announced the signing of an agreement to acquire REMP AG, a wholly-owned subsidiary of Tecan, as well as other related assets. Under this agreement, NEXUS will acquire all activities of Tecan's REMP ® Sample Management business segment from Tecan.  REMP, based in Oberdiessbach, Switzerland, is a leading global provider of sample management systems and related sample management devices, instruments and consumables.  In parallel with this transaction, Tecan and NEXUS plan to collaborate on various additional product groups. The transaction should be closed within the next 2 months.

John Lillig‚ CEO of NEXUS Biosystems, commented: "We are delighted with the opportunity to broaden our automated chemical and biological sample management offerings with the acquisition of Tecan's REMP Sample Management business. Together with our new colleagues from REMP, we look forward to continuing to provide innovative and reliable sample management solutions for our customers in the biopharmaceutical, biorepository, diagnostic, forensic, agrochemical and genomic research centers throughout the world.   The combined NEXUS-REMP resources will strengthen our capabilities and ensure continuity of first-class service and support for our customers as well as expand our product offerings for the growing global sample management community.  As a key part of this opportunity we also look forward to furthering our collaborations with our colleagues at Tecan."

Thomas Bachmann, CEO of Tecan, commented: "We are certain that the sale of REMP to NEXUS Biosystems is the ideal solution. Our customers will benefit from the strong global market and service presence and the unparalleled innovation strength of the combined NEXUS-REMP entity in this industry segment. At Tecan, we will increasingly focus resources on growth projects in our Life Sciences core markets and actively expand our end-customer business and our OEM activities."

Complementary products and markets

NEXUS Biosystems is one of the world's leading providers of automated sample management systems and technologies for the biopharmaceutical, biorepository and related research communities around the world. NEXUS' majority investor is Telegraph Hill Partners, a life science and medical products growth equity investment company based in San Francisco (California, USA).

NEXUS and REMP complement one another, with NEXUS having strengths in high speed, mid-size sample management systems and high performance microtiter plates, while REMP is a leader in small and large size automated sample management systems and high quality sample containers and consumables.  REMP has a strong customer base in Europe and Asia with a growing presence in the USA, while NEXUS enjoys a strong position in the USA with a growing presence in Europe and Asia.

About NEXUS Biosystems:

NEXUS Biosystems ( is a leading innovator and worldwide provider of enabling technologies and automated sample management systems for pharmaceutical, biotech, biorepository, agrochemical and related research institutions worldwide.  NEXUS products include the Universal Store family of automated ambient, -20°C and -80°C chemical and biological sample management systems, the Aurora line of high performance microplates, the XPeel microplate de-sealer, and the Crystal Farm line of protein crystallization systems.  NEXUS was founded in 2005, is headquartered in Poway, CA, has a European subsidiary NEXUS Biosystems GmbH in Munich, Germany, and has sales and distribution offices throughout the US, Europe and Asia.

About Tecan

Tecan ( is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics. The company specializes in the development, production and distribution of instruments and automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer, Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2009, Tecan generated sales of CHF 392 million (USD 361.2 million; EUR 259.6 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters: TECZn.S/ ISIN CH0012100191).

About Telegraph Hill Partners:

Telegraph Hill Partners, based in San Francisco, CA, is a private equity investment firm specializing in life science and medical device businesses. The firm partners with private companies that demonstrate strong financial performance and innovative products or services. Additional information can be found at

SOURCE NEXUS Biosystems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies
2. AACR Data Highlights InNexus Preclinical Antibody Candidate
3. Incept BioSystems Initiates First Human Clinical Trial of its SMART Embryo Culture System for In Vitro Fertilization (IVF)
4. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
5. Image Solutions, Inc. Acquires Zurich Biostatistics, Inc.
6. U.S. Preventive Medicine Acquires Specialty Disease Management
7. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
8. Nastech Reacquires Teriparatide (Parathyroid Hormone; PTH1-34) Nasal Spray from Procter & Gamble
9. Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels
10. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim
11. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim and Manufacturing Facility From PLIVA
Post Your Comments:
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
(Date:11/25/2015)...  Today AVACEN Medical announced the issue of United States patent No. ... ". This patent shields the company,s AVACEN 100 dry heat therapy medical device and specific methods ... Photo - ... ... ...
(Date:11/25/2015)... , Nov. 25, 2015 USP 800 ... drug preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, ... technicians). The chapter also covers all entities which ... pharmacies, hospitals, other healthcare institutions, patient treatment clinics, ... --> --> What is ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert ... Organizations, One Beat ” campaign. The partnership between the two groups began in 2014 ... MAP International’s cause. , MAP International was founded in 1954 and is an international ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug rehabilitation ... new cutting edge recovery program that has been 50 years in the making. ... with the purpose to free addicts from the symptoms and negative behaviors of addiction. ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for ... aware of the benefits of Botox® in the treatment of moderate facial wrinkling, few ... and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by an ... IL, UV Angel is evaluating the efficacy of its product and its disinfection protocol. ... 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical ...
(Date:11/25/2015)... Spring, Md (PRWEB) , ... November 25, 2015 ... ... Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible ... history of this disease. The Periwinkle Pioneers, nominated by the public, will receive ...
Breaking Medicine News(10 mins):